TABLE1 1.
Clinical characteristics of study population
| BMI ≤ 24.9 (n = 14) | BMI > 24.9 (n = 23) | P value | |
|---|---|---|---|
| Gender (female, %) | 36 | 30 | 0.7 |
| Age (y) | 61 (4) | 62 (6) | 0.4 |
| BMI (kg/m2) | 21 (2) | 29 (3) | < 0.0001 |
| Current smokers (%) | 71 | 40 | 0.06 |
| Pack years | 42 (15) | 39 (14) | 0.5 |
| FEV1 (L) | 2.0 (0.4) | 1.9 (0.4) | 0.3 |
| FEV1 (%) | 68 (11) | 63 (11) | 0.2 |
| FEV1/FVC ratio | 0.51 (0.06) | 0.52 (0.1) | 0.7 |
| ICS (%) | 64 | 70 | 0.7 |
| LABA (%) | 50 | 70 | 0.2 |
| LAMA (%) | 57 | 61 | 0.8 |
| Total SGRQ | 35 (21) | 42 (18) | 0.3 |
| CAT | 19 (9) | 17 (9) | 0.7 |
| mMRC | 1.0 (1.0) | 1.9 (1.1) | 0.02 |
| Exacerbation rate 12 months prior | 0.9 (1.2) | 0.7 (1.0) | 0.5 |
Data presented as % or mean ± SD.
CAT, COPD Assessment Test, FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; ICS, inhaled corticosteroids; LABA, long‐acting beta 2 agonist; LAMA, long‐acting muscarinic antagonist; mMRC, modified Medical Research Council; SGRQ, St George’s Respiratory Questionnaire.